Cover Image
市場調查報告書

癌症性疼痛:開發中產品分析

Cancer Pain - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 192514
出版日期 內容資訊 英文 131 Pages
訂單完成後即時交付
價格
Back to Top
癌症性疼痛:開發中產品分析 Cancer Pain - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 131 Pages
簡介

所謂癌症疼痛定義是指癌症對人體造成損傷,人體對這個損傷的各種反應之複雜組成的感覺。腫瘤對人體造成壓迫或侵蝕、為了治療、診斷所做的處置、免疫反應或荷爾蒙釋出造成皮膚、神經等病變皆可能引發疼痛。可使用止痛劑療法或Opioids(類鴉片物質)止痛藥、佐劑(佐藥)、心理治療、麻醉學·神經外科性疼痛管理手法等,來治療癌症疼痛。

本報告提供全球各國治療癌症性疼痛所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

癌症性疼痛:概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9307IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Pipeline Review, H1 2017, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape.

Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 8, 5, 3, 1, 20, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Cancer Pain - Overview
  • Cancer Pain - Therapeutics Development
  • Cancer Pain - Therapeutics Assessment
  • Cancer Pain - Companies Involved in Therapeutics Development
  • Cancer Pain - Drug Profiles
  • Cancer Pain - Dormant Projects
  • Cancer Pain - Discontinued Products
  • Cancer Pain - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Cancer Pain, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Cancer Pain - Pipeline by Alexza Pharmaceuticals Inc, H1 2017
  • Cancer Pain - Pipeline by AngioChem Inc, H1 2017
  • Cancer Pain - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017
  • Cancer Pain - Pipeline by Aphios Corp, H1 2017
  • Cancer Pain - Pipeline by AstraZeneca Plc, H1 2017
  • Cancer Pain - Pipeline by ChironWells GmbH, H1 2017
  • Cancer Pain - Pipeline by Colby Pharmaceutical Company, H1 2017
  • Cancer Pain - Pipeline by ConSynance Therapeutics Inc, H1 2017
  • Cancer Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Cancer Pain - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Cancer Pain - Pipeline by Dompe Farmaceutici SpA, H1 2017
  • Cancer Pain - Pipeline by Fujimoto Pharmaceutical Corp, H1 2017
  • Cancer Pain - Pipeline by Grunenthal GmbH, H1 2017
  • Cancer Pain - Pipeline by GW Pharmaceuticals Plc, H1 2017
  • Cancer Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2017
  • Cancer Pain - Pipeline by Immupharma Plc, H1 2017
  • Cancer Pain - Pipeline by Insys Therapeutics Inc, H1 2017
  • Cancer Pain - Pipeline by IntelGenx Corp, H1 2017
  • Cancer Pain - Pipeline by iX Biopharma Ltd, H1 2017
  • Cancer Pain - Pipeline by Kancera AB, H1 2017
  • Cancer Pain - Pipeline by Klaria Pharma Holding AB, H1 2017
  • Cancer Pain - Pipeline by Komipharm International Co Ltd, H1 2017
  • Cancer Pain - Pipeline by KPI Therapeutics Inc, H1 2017
  • Cancer Pain - Pipeline by Medlab Clinical Ltd, H1 2017
  • Cancer Pain - Pipeline by Nanomerics Ltd, H1 2017
  • Cancer Pain - Pipeline by Neurocentrx Pharma Ltd, H1 2017
  • Cancer Pain - Pipeline by Nippon Kayaku Co Ltd, H1 2017
  • Cancer Pain - Pipeline by Orion Oyj, H1 2017
  • Cancer Pain - Pipeline by Pain Therapeutics Inc, H1 2017
  • Cancer Pain - Pipeline by Pfizer Inc, H1 2017
  • Cancer Pain - Pipeline by Pharmaleads SA, H1 2017
  • Cancer Pain - Pipeline by Recordati SpA, H1 2017
  • Cancer Pain - Pipeline by Ribomic Inc, H1 2017
  • Cancer Pain - Pipeline by Trillium Therapeutics Inc, H1 2017
  • Cancer Pain - Pipeline by Virobay Inc, H1 2017
  • Cancer Pain - Pipeline by WEX Pharmaceuticals Inc, H1 2017
  • Cancer Pain - Dormant Projects, H1 2017
  • Cancer Pain - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Cancer Pain - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Cancer Pain - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Cancer Pain, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top